Ben Gil Price - Net Worth and Insider Trading
Ben Gil Price Net Worth
The estimated net worth of Ben Gil Price is at least $6 Million dollars as of 2024-05-06. Ben Gil Price is the Director of Sarepta Therapeutics Inc and owns about 42,830 shares of Sarepta Therapeutics Inc (SRPT) stock worth over $6 Million. Ben Gil Price is also the Director of Rexahn Pharmaceuticals Inc and owns about 312 shares of Rexahn Pharmaceuticals Inc (REXN) stock worth over $2,259. Details can be seen in Ben Gil Price's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ben Gil Price has not made any transactions after 2019-01-29 and currently still holds the listed stock(s).
Transaction Summary of Ben Gil Price
Ben Gil Price Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ben Gil Price owns 4 companies in total, including Rexahn Pharmaceuticals Inc (REXN) , Sarepta Therapeutics Inc (SRPT) , and Ocuphire Pharma Inc (OCUP) among others .
Click here to see the complete history of Ben Gil Price’s form 4 insider trades.
Insider Ownership Summary of Ben Gil Price
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| REXN | Rexahn Pharmaceuticals Inc | 2019-06-06 | director |
| SRPT | Sarepta Therapeutics Inc | 2016-03-14 | director |
| OCUP | Ocuphire Pharma Inc | 2018-11-29 | director |
 | | 2021-11-03 | CEO and President |
Ben Gil Price Latest Holdings Summary
Ben Gil Price currently owns a total of 2 stocks. Among these stocks, Ben Gil Price owns 42,830 shares of Sarepta Therapeutics Inc (SRPT) as of March 14, 2016, with a value of $6 Million and a weighting of 99.96%. Ben Gil Price also owns 312 shares of Rexahn Pharmaceuticals Inc (REXN) as of January 29, 2019, with a value of $2,259 and a weighting of 0.04%.
Latest Holdings of Ben Gil Price
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc | 2016-03-14 | 42,830 | 133.23 | 5,706,241 |
| REXN | Rexahn Pharmaceuticals Inc | 2019-01-29 | 312 | 7.24 | 2,259 |
Holding Weightings of Ben Gil Price
Ben Gil Price Form 4 Trading Tracker
According to the SEC Form 4 filings, Ben Gil Price has made a total of 0 transactions in Sarepta Therapeutics Inc (SRPT) over the past 5 years. The most-recent trade in Sarepta Therapeutics Inc is the acquisition of 4,500 shares on March 14, 2016, which cost Ben Gil Price around $75,150.
According to the SEC Form 4 filings, Ben Gil Price has made a total of 0 transactions in Rexahn Pharmaceuticals Inc (REXN) over the past 5 years. The most-recent trade in Rexahn Pharmaceuticals Inc is the acquisition of 312 shares on January 29, 2019, which cost Ben Gil Price around $9,150.
Insider Trading History of Ben Gil Price
- 1
Ben Gil Price Trading Performance
GuruFocus tracks the stock performance after each of Ben Gil Price's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ben Gil Price is 4.15%. GuruFocus also compares Ben Gil Price's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ben Gil Price within 3 months outperforms 5 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ben Gil Price's insider trading performs compared to the benchmark.
Performance of Ben Gil Price
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 4.33 | | | | | |
| Relative Return to S&P 500(%) | 4.17 | | | | | |
Ben Gil Price Ownership Network
Ben Gil Price Owned Company Details
What does Rexahn Pharmaceuticals Inc do?
Who are the key executives at Rexahn Pharmaceuticals Inc?
Ben Gil Price is the director of Rexahn Pharmaceuticals Inc. Other key executives at Rexahn Pharmaceuticals Inc include Chief Medical Officer Ely Benaim , Chief Business Officer Lisa Nolan , and director & President and CEO Douglas J Swirsky .
Rexahn Pharmaceuticals Inc (REXN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Rexahn Pharmaceuticals Inc (REXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rexahn Pharmaceuticals Inc (REXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Rexahn Pharmaceuticals Inc (REXN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rexahn Pharmaceuticals Inc Insider Transactions
Ben Gil Price Mailing Address
Above is the net worth, insider trading, and ownership report for Ben Gil Price. You might contact Ben Gil Price via mailing address: 8297 Champions Gate Blvd. #444, Champions Gate Fl 33896.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
